The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Apr. 27, 12:02 AM

Slide #8. SCYNEXIS Secondary Offering

Company: SCYNEXIS (NASDAQ:SCYX)
Date announced: 4/20/2015
Shares Offered: 4,675,324
Date of Pricing: 4/22/2015
Price Per Share: $7.70
Secondary Offering Details: SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the commencement of an underwritten public offering of shares of its common stock and expects to raise gross proceeds of up to $30 million. The company expects to grant the underwriter a 30-day option to purchase up to an additional $4.5 million of shares of its common stock in connection with the offering. All of the shares of common stock in the offering will be sold by SCYNEXIS. - updated 2/23 - Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 4,675,324 shares of its common stock at a public offering price of $7.70 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 701,298 shares of common stock at the public offering price less the underwriting discounts and commissions to cover over-allotments, if any.

SCYNEXIS is a chemistry-focused drug discovery and development company. Co. engages in the discovery, development and commercialization of anti-infectives to address therapeutic needs. Co. is developing a product, SCY-078, as an oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, Co. has clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. It also provides contract research and development services in the field of animal health.
Open the SCYX Page at The Online Investor »

Company Name:  SCYNEXIS, Inc.
Website:  www.scynexis.com
Sector:  Drugs & Pharmaceuticals
 

Open the SCYX Page at The Online Investor (in a new window) »

April 27, 2015    12:02 AM Eastern
Quotes delayed 20 minutes


Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.